X0306 4/A 2020-01-31 2020-01-31 false 0001689813 Biohaven Pharmaceutical Holding Co Ltd. BHVN 0001448914 Heffernan Michael Thomas C/O BIOHAVEN PHARMACEUTICALS, INC. 215 CHURCH STREET NEW HAVEN CT 06510 true false false false Stock Option (right to buy) 48.49 2020-01-31 4 A false 26200.00 0.00 A 2030-01-31 Common Shares 26200.00 26200.00 D Stock Option (Right to Buy) 47.10 2020-04-30 4 A false 0.00 0.00 A 2030-04-29 Common Shares 0.00 0.00 D On January 31, 2020, the reporting person filed a Form 4 in respect of 36,000 options granted pursuant to the issuer's non-employee director compensation policy. The issuer subsequently determined that 9,800 of the options comprising such award were null and void upon grant as a result of the $1,000,000 annual limit for non-employee director compensation under its 2017 Equity Incentive Plan. This option grant was made pursuant to the issuer's non-employee director compensation policy. The common shares underlying this option vest in three equal installments on January 31, 2021, 2022 and 2023, subject to the reporting person's continuous service with the issuer at each vesting date. On May 1, 2020, the reporting person filed a Form 4 in respect of 18,000 options granted pursuant to the issuer's non-employee director compensation policy. The issuer subsequently determined that all 18,000 of the options comprising such award were null and void upon grant as a result of the $1,000,000 annual limit for non-employee director compensation under its 2017 Equity Incentive Plan. The shares subject to this stock option will vest in full on the earlier of (a) April 30, 2021 or (b) the date of the 2021 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date. /s/ Jim Engelhart, Attorney-in-Fact 2021-03-26